Wednesday, January 12, 2022 Daily Archives

Takeda drives immuno-oncology portfolio with Adaptate buy

by

The acquisition will add Adaptate’s novel antibody-based delta T-cell engager platform to Takeda’s immune-oncology portfolio. Takeda is set to acquire UK firm Adaptate Biotherapeutics, a company focused on developing antibody-based therapeutics for the adaptation of variable delta 1 (Vδ1) gamma delta (γδ) T cells. In addition to gaining Adaptate’s antibody-based γδ T cell engager platform, Takeda will also obtain its preclinical candidate and discovery pipeline programs. “Adaptate’s γδ T-cell engagers are engineered to specifically activate a γδ T cell-mediated immune…

January 12, 2022

The Production and Application of Antibody Fragments

by

Antibodies are modular defense systems that identify and neutralize foreign objects like bacteria and viruses. In addition to oncology and inflammation, antibodies are now recognized as routine molecules in many therapeutic fields. Antibody fragments, in particular the Fabs, scFvs and VHH retain full antigen-binding capacity and superior properties for research, diagnostic and therapeutic applications. They have a smaller size that enables their binding to hidden epitopes not accessible to whole antibodies. In the context of therapeutic applications, a small molecular…

January 12, 2022